Study of NEO-201 in Solid Tumors Expansion Cohorts

This study is testing a new drug called NEO-201 in patients with specific advanced solid tumors — including non-small cell lung cancer, head and neck cancer, uterine cancer, and cervical cancer — whose cancer has returned or spread despite standard treatments. **You may be eligible if...** - You are 18 or older - You have confirmed advanced, unresectable, or metastatic cancer in one of these specific types: non-small cell lung cancer, head and neck squamous cell carcinoma (HNSCC), uterine cancer, or cervical cancer - Your tumor tests positive for the NEO-201 target protein (at least 10% of tumor cells) - Your cancer has progressed during or after at least one prior standard treatment (chemotherapy and/or targeted therapy) - You cannot be cured by surgery or radiation - Your disease is measurable on scans - For lung cancer: your tumor must express PD-L1 or have specific genetic features; patients with EGFR/ALK/ROS1/BRAF mutations must have already tried approved targeted drugs **You may NOT be eligible if...** - Your tumor does not express the NEO-201 target - You have not yet tried standard first-line treatments appropriate for your cancer type - You are unable or unwilling to provide tumor tissue for testing Talk to your doctor to see if this trial is right for you.